Table 1 Characteristics at randomization.
Pre-randomization Characteristics | Placebo | Furosemide Low-dose | Furosemide High-dose |
|---|---|---|---|
Weight (g) | 335 (323–343) | 354 (347–360) | 331 (321–349) |
P/F-ratio | 398 (388–449) | 401 (396–420) | 427 (400–489) |
LVEDP (mmHg) | 12.5 (10.8–13.9) | 12.2 (8.8–16.5) | 13.4 (12.8–17.0) |
Heart rate (min−1) | 244 (233–249) | 252 (241–261) | 251 (238–255) |
MAP (mmHg) | 62 (59–65) | 61 (59–63) | 63 (61–67) |
LVPmax (mmHg) | 99 (95–110) | 101 (99–102) | 97 (92–100) |
SV (μL) | 76 (65–94) | 83 (67–95) | 69 (61–79) |
Ejection fraction (%) | 49 (41–67) | 59 (58–64) | 42 (37–49) |
MI size (%) | 38.7 (35.7.–41.5) | 34.6 (32.0–34.7) | 37.6 (34.6–40.3) |
RPP (mmHg min−1 103) | 25.6 (23.0–26.9) | 24.7 (23.8–26.3) | 24.4 (23.7–25.7) |
Stroke work (mmHg μL 103) | 7.1 ± 1.9 | 7.1 ± 1.5 | 5.6 ± 1.3 |
CVP (mmHg) | 5.1 (4.0–6.0) | 4.24 (4.0–6.0) | 6.1 (5.9–6.6) |
SVR (dyn s cm−5) | 251 (201–278) | 213 (186–264) | 264 (224–335) |
Noradrenaline (μg kg−1) | 0.96 ± 0.16 | 0.91 ± 0.16 | 0.79 ± 0.10 |
Fluid balance (mL) | 2.6 ± 0.2 | 2.9 ± 0.3 | 2.3 ± 0.2 |
